Nadeem Najam, MD
Nephrology · Indianapolis, INNPI 1982669495
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,545 of the $4,354 with a category attached, or 81.4%. 23 manufacturers reported payments, led by Medtronic at 44.2% of the total. Reporting peaked in 2022 at $1,772 and has fallen 53.7% since, to $820 in 2025.
Across 108 payments — averaging $40.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Bard Peripheral Vascular, Inc.$678
- Novartis$295
- AstraZeneca$264
- Vantive US Healthcare LLC$177
- Aurinia Pharma U.S., Inc.$169
- plus $848 from 17 others
What the payments were for
- Travel & lodging$79618%
- Food & beverage$3,54581%
- Education$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 25 | $1,924 |
| Bard Peripheral Vascular, Inc. | 14 | $678 |
| Novartis | 15 | $295 |
| AstraZeneca | 12 | $264 |
| Vantive US Healthcare LLC | 2 | $177 |
| Aurinia Pharma U.S., Inc. | 4 | $169 |
| Mallinckrodt Enterprises LLC | 1 | $121 |
| Amgen(2 entities) | 6 | $101 |
| Nxstage Medical, Inc. | 2 | $91 |
| Bayer | 3 | $73 |
| Otsuka America Pharmaceutical, Inc. | 3 | $68 |
| OPKO Pharmaceuticals, LLC | 4 | $61 |
| Boehringer Ingelheim | 3 | $53 |
| Fresenius USA Marketing, Inc. | 3 | $40 |
| Novo Nordisk | 2 | $40 |
| Covidien LP | 1 | $40 |
| Travere Therapeutics, Inc. | 2 | $28 |
| Arjo Inc. | 1 | $27 |
| Philips North America LLC | 1 | $26 |
| Vifor Pharma, Inc. | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Akebia Therapeutics Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELLIPSYS VASCULAR ACCESS SYSTEM$1,272
- COVERA$130
- ACTHAR$121
- LUPKYNIS$116
How this compares
$4,354 in reported general payments places this provider in the 80th percentile of 238 nephrology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 29 | $25,068 |
| JardianceEmpagliflozin | 20 | $15,715 |
| ClinolipidFat Emulsion/Olive/Soy/Phospho | 18 | $5,809 |
| Bumetanide | 100 | $1,440 |
| Valsartan | 18 | $572 |
| Amlodipine Besylate | 55 | $349 |
| Losartan Potassium | 72 | $342 |
| Chlorthalidone | 34 | $316 |
| Tamsulosin Hcl | 34 | $274 |
| Lisinopril | 52 | $107 |
| Furosemide | 38 | $60 |
| Spironolactone | 15 | $42 |
| Metoprolol Succinate | 29 | $33 |
| Carvedilol | 28 | $30 |
| Hydrochlorothiazide | 14 | $14 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $264 | $25,06829 claims |
| Boehringer IngelheimJardiance | $53 | $15,71520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 238 nephrology providers in Indiana.
Other nephrology in Indianapolis
- Rajiv AgarwalIndianapolis$1.2M
- Jay WishIndianapolis$502K
- Bruce MolitorisIndianapolis$108K
- Michael KrausIndianapolis$92K
- Muhammad MujtabaIndianapolis$71K
- Simit DoshiIndianapolis$63K
- Arjun SinhaIndianapolis$50K
- Brent MillerIndianapolis$46K
- James ElliottIndianapolis$37K
- Nupur GuptaIndianapolis$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.